{"id":1612,"date":"2022-09-27T12:00:10","date_gmt":"2022-09-27T10:00:10","guid":{"rendered":"https:\/\/dextechmedical.com\/?p=1612"},"modified":"2022-09-27T11:31:42","modified_gmt":"2022-09-27T09:31:42","slug":"dextech-medical-announces-upcoming-multiple-myeloma-study","status":"publish","type":"post","link":"https:\/\/dextechmedical.com\/en\/dextech-medical-announces-upcoming-multiple-myeloma-study\/","title":{"rendered":"DexTech Medical announces upcoming multiple myeloma study"},"content":{"rendered":"
\n
\n
\n

The application for an Fas1 study regarding the effect of OsteoDex on patients with multiple myeloma (MM) was approved and granted permission by the Medical Products Agency on August 10, 2022. The study will include 20 patients and be conducted at 4-5 hospitals in Sweden and other Nordic countries. Studyn is expected to start in Q1 2023 and be completed during Q4, 2024. Principal investigator (PI) is Dr Katarina Uttervall, MD, PhD, Division of Hematology\/HERM, Karolinska University Hospital, Huddinge. The main blood markers will be analyzed at the Central Laboratory, Karolinska University Hospital, NKS, Solna. The study duration for each individual patient is 14 weeks, from screening to follow-up visits. Each patient will receive OsteoDex every two weeks, a maximum of 7 doses. Adult MM patients with recurrent\/treatment-resistant disease, who received 1-3 previous lines of therapy, will be included. The primary objective is to confirm safety and tolerability. The secondary objective is to determine treatmentresponse, change in the level of disease-related biomarkers, and documentation of quality of life (QoL scores).<\/p>\n

For more information about DexTech, please contact:<\/strong><\/p>\n

Go\u0308sta Lundgren \u2013 CFO
\nDexTech Medical AB
\nPhone: +46 (0) 707104788
\nE-post: gosta.lundgren@dextechmedical.com<\/p>\n

This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on September 27, 2022.<\/em><\/p>\n

220927 – PR – DexTech – myeloma study<\/a><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

The application for an Fas1 study regarding the effect of OsteoDex on patients with multiple myeloma (MM) was approved and granted permission by the Medical Products Agency on August 10, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-1612","post","type-post","status-publish","format-standard","hentry","category-okategoriserade-en"],"acf":[],"yoast_head":"\nDexTech Medical announces upcoming multiple myeloma study | DexTech<\/title>\n<meta name=\"description\" content=\"The application for an Fas1 study regarding the effect of OsteoDex on patients with multiple myeloma (MM) was approved and granted permission by the\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dextechmedical.com\/?p=1607\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DexTech Medical announces upcoming multiple myeloma study | DexTech\" \/>\n<meta property=\"og:description\" content=\"The application for an Fas1 study regarding the effect of OsteoDex on patients with multiple myeloma (MM) was approved and granted permission by the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dextechmedical.com\/?p=1607\" \/>\n<meta property=\"og:site_name\" content=\"DexTech\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-27T10:00:10+00:00\" \/>\n<meta name=\"author\" content=\"G\u00f6sta Lundgren\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G\u00f6sta Lundgren\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dextechmedical.com\/?p=1607\",\"url\":\"https:\/\/dextechmedical.com\/?p=1607\",\"name\":\"DexTech Medical announces upcoming multiple myeloma study | DexTech\",\"isPartOf\":{\"@id\":\"https:\/\/dextechmedical.com\/#website\"},\"datePublished\":\"2022-09-27T10:00:10+00:00\",\"author\":{\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\"},\"description\":\"The application for an Fas1 study regarding the effect of OsteoDex on patients with multiple myeloma (MM) was approved and granted permission by the\",\"breadcrumb\":{\"@id\":\"https:\/\/dextechmedical.com\/?p=1607#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dextechmedical.com\/?p=1607\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dextechmedical.com\/?p=1607#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dextechmedical.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DexTech Medical announces upcoming multiple myeloma study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dextechmedical.com\/#website\",\"url\":\"https:\/\/dextechmedical.com\/\",\"name\":\"DexTech\",\"description\":\"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dextechmedical.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\",\"name\":\"G\u00f6sta Lundgren\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"caption\":\"G\u00f6sta Lundgren\"},\"sameAs\":[\"https:\/\/dextechmedical.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DexTech Medical announces upcoming multiple myeloma study | DexTech","description":"The application for an Fas1 study regarding the effect of OsteoDex on patients with multiple myeloma (MM) was approved and granted permission by the","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dextechmedical.com\/?p=1607","og_locale":"en_US","og_type":"article","og_title":"DexTech Medical announces upcoming multiple myeloma study | DexTech","og_description":"The application for an Fas1 study regarding the effect of OsteoDex on patients with multiple myeloma (MM) was approved and granted permission by the","og_url":"https:\/\/dextechmedical.com\/?p=1607","og_site_name":"DexTech","article_published_time":"2022-09-27T10:00:10+00:00","author":"G\u00f6sta Lundgren","twitter_misc":{"Written by":"G\u00f6sta Lundgren","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dextechmedical.com\/?p=1607","url":"https:\/\/dextechmedical.com\/?p=1607","name":"DexTech Medical announces upcoming multiple myeloma study | DexTech","isPartOf":{"@id":"https:\/\/dextechmedical.com\/#website"},"datePublished":"2022-09-27T10:00:10+00:00","author":{"@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c"},"description":"The application for an Fas1 study regarding the effect of OsteoDex on patients with multiple myeloma (MM) was approved and granted permission by the","breadcrumb":{"@id":"https:\/\/dextechmedical.com\/?p=1607#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dextechmedical.com\/?p=1607"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dextechmedical.com\/?p=1607#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dextechmedical.com\/en\/"},{"@type":"ListItem","position":2,"name":"DexTech Medical announces upcoming multiple myeloma study"}]},{"@type":"WebSite","@id":"https:\/\/dextechmedical.com\/#website","url":"https:\/\/dextechmedical.com\/","name":"DexTech","description":"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dextechmedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c","name":"G\u00f6sta Lundgren","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","caption":"G\u00f6sta Lundgren"},"sameAs":["https:\/\/dextechmedical.com"]}]}},"_links":{"self":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/comments?post=1612"}],"version-history":[{"count":1,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1612\/revisions"}],"predecessor-version":[{"id":1615,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1612\/revisions\/1615"}],"wp:attachment":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media?parent=1612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/categories?post=1612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/tags?post=1612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}